99 related articles for article (PubMed ID: 8929570)
21. Human platelet 20S proteasome: inhibition of its chymotrypsin-like activity and identification of the proteasome activator PA28. A preliminary report.
Ostrowska H; Ostrowska JK; Worowski K; Radziwon P
Platelets; 2003 May; 14(3):151-7. PubMed ID: 12850839
[TBL] [Abstract][Full Text] [Related]
22. A novel chymotrypsin-like component of the multicatalytic proteinase complex optimally active at acidic pH.
Figueiredo-Pereira ME; Chen WE; Yuan HM; Wilk S
Arch Biochem Biophys; 1995 Feb; 317(1):69-78. PubMed ID: 7872805
[TBL] [Abstract][Full Text] [Related]
23. Modulation of the chymotrypsin-like activity of the 20S proteasome by intracellular redox status: effects of glutathione peroxidase-1 overexpression and antioxidant drugs.
Kretz-Remy C; Arrigo AP
Biol Chem; 2003 Apr; 384(4):589-95. PubMed ID: 12751788
[TBL] [Abstract][Full Text] [Related]
24. Characterization of cytochrome P4502E1 turnover in transfected HepG2 cells expressing human CYP2E1.
Yang MX; Cederbaum AI
Arch Biochem Biophys; 1997 May; 341(1):25-33. PubMed ID: 9143349
[TBL] [Abstract][Full Text] [Related]
25. Evidence for the existence of a proteasome in Toxoplasma gondii: intracellular localization and specific peptidase activities.
Paugam A; Creuzet C; Dupouy-Camet J; Roisin MP
Parasite; 2001 Dec; 8(4):267-73. PubMed ID: 11802263
[TBL] [Abstract][Full Text] [Related]
26. Activity and regulation of the centrosome-associated proteasome.
Fabunmi RP; Wigley WC; Thomas PJ; DeMartino GN
J Biol Chem; 2000 Jan; 275(1):409-13. PubMed ID: 10617632
[TBL] [Abstract][Full Text] [Related]
27. Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway.
Mori S; Tanaka K; Omura S; Saito Y
J Biol Chem; 1995 Dec; 270(49):29447-52. PubMed ID: 7493983
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin A and chymotrypsin-like activity of the proteasome in human blood platelets.
Ostrowska H; Wójcik C; Worowski K
Folia Histochem Cytobiol; 1999; 37(2):153-4. PubMed ID: 10353004
[No Abstract] [Full Text] [Related]
29. Proteasome inhibitors which induce neurite outgrowth from PC12h cells cause different subcellular accumulations of multi-ubiquitin chains.
Ohtani-Kaneko R; Takada K; Iigo M; Hara M; Yokosawa H; Kawashima S; Ohkawa K; Hirata K
Neurochem Res; 1998 Nov; 23(11):1435-43. PubMed ID: 9814555
[TBL] [Abstract][Full Text] [Related]
30. The 26 S proteasome is activated at two points in the ascidian cell cycle.
Kawahara H; Sawada H; Yokosawa H
FEBS Lett; 1992 Sep; 310(2):119-22. PubMed ID: 1397259
[TBL] [Abstract][Full Text] [Related]
31. Ubiquitinated proteasome inhibitor is a component of the 26 S proteasome complex.
Li XS; Etlinger JD
Biochemistry; 1992 Dec; 31(48):11964-7. PubMed ID: 1333790
[TBL] [Abstract][Full Text] [Related]
32. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients.
Bossola M; Muscaritoli M; Costelli P; Grieco G; Bonelli G; Pacelli F; Rossi Fanelli F; Doglietto GB; Baccino FM
Ann Surg; 2003 Mar; 237(3):384-9. PubMed ID: 12616123
[TBL] [Abstract][Full Text] [Related]
33. Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex.
Cardinale A; Filesi I; Biocca S
Eur J Biochem; 2001 Jan; 268(2):268-77. PubMed ID: 11168360
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer's disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome.
Christie G; Markwell RE; Gray CW; Smith L; Godfrey F; Mansfield F; Wadsworth H; King R; McLaughlin M; Cooper DG; Ward RV; Howlett DR; Hartmann T; Lichtenthaler SF; Beyreuther K; Underwood J; Gribble SK; Cappai R; Masters CL; Tamaoka A; Gardner RL; Rivett AJ; Karran EH; Allsop D
J Neurochem; 1999 Jul; 73(1):195-204. PubMed ID: 10386971
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met.
Kermorgant S; Zicha D; Parker PJ
J Biol Chem; 2003 Aug; 278(31):28921-9. PubMed ID: 12716900
[TBL] [Abstract][Full Text] [Related]
36. Proteasome activator (PA28) subunits, alpha, beta and gamma (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells.
Wójcik C; Tanaka K; Paweletz N; Naab U; Wilk S
Eur J Cell Biol; 1998 Oct; 77(2):151-60. PubMed ID: 9840465
[TBL] [Abstract][Full Text] [Related]
37. Pitfalls in invertebrate proteasome assays.
Götze S; Bose A; Abele D; Sokolova IM; Saborowski R
J Exp Biol; 2013 Apr; 216(Pt 8):1351-4. PubMed ID: 23264486
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome.
Wójcik C; Stoklosa T; Giermasz A; Golab J; Zagozdzon R; Kawiak J; Wilk S; Komar A; Kaca A; Malejczyk J; Jakóbisiak M
Apoptosis; 1997; 2(5):455-62. PubMed ID: 14646528
[TBL] [Abstract][Full Text] [Related]
39. In-gel proteasome assay to determine the activity, amount, and composition of proteasome complexes from mammalian cells or tissues.
Yazgili AS; Meul T; Welk V; Semren N; Kammerl IE; Meiners S
STAR Protoc; 2021 Jun; 2(2):100526. PubMed ID: 34027484
[TBL] [Abstract][Full Text] [Related]
40. TRIM25 targets p300 for degradation.
Elabd S; Pauletto E; Solozobova V; Eickhoff N; Padrao N; Zwart W; Blattner C
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37770115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
